INGREZZA® (valbenazine) capsules is a once-daily treatment for adults with tardive dyskinesia
Help your adult patients with Tardive Dyskinesia (TD)


Not actual size

INGREZZA is the simple, once-daily choice to reduce TD severity1
Actor portrayal
UNIQUELY
SELECTIVE
Only INGREZZA exclusively delivers one primary metabolite (+ α) for potent and selective inhibition of VMAT21-3,*
EXPLOREPHARMACOLOGY
PROVEN
EFFICACY
INGREZZA 80 mg reduced uncontrolled movements in 7 of 10 patients at 6 weeks (post hoc analysis)1,4,†
REVIEW EFFICACYTHE SIMPLE
CHOICE
The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1
EXPLORE DOSINGSAVINGS &
SUPPORT
$10 or less out-of-pocket is what most patients pay for INGREZZA5
SEE SUPPORT OPTIONS* | Based on in vitro VMAT2 binding affinity of dihydrotetrabenazine (HTBZ) metabolites and INGREZZA’s primary active metabolite, + α HTBZ. The clinical significance of in vitro data is unknown and is not meant to imply clinical outcomes. |
† | Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score. |

TREAT FIRST LINE WITH VMAT2 INHIBITORS
VMAT2 inhibitors, like INGREZZA, are recommended as first-line treatment for TD6-8
SEE GUIDELINESCONNECT WITH A
REPRESENTATIVE
Request an office visit from a Neurocrine representative for additional information, patient resources, or samples of INGREZZA.
CONTACT A REPREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc
- Harriott ND, Williams JP, Smith EB, Bozigian HP, Grigoriadis DE. VMAT2 inhibitors and the path to INGREZZA (valbenazine). Prog Med Chem. 2018;57(1):87-111
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361(3):454-461
- Data on file. Neurocrine Biosciences, Inc
- Data on file as of Q4 2022. Neurocrine Biosciences, Inc
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing, 2020
- Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75
- Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983